Erratum: Candidate genes expression profile associated with antidepressants response in the GENDEP study: Differentiating between baseline predictors and longitudinal targets (Neuropsychopharmacology (2013) 38 (376) DOI: 10.1038/npp.2012.191);Candidate genes expression profile associated with antidepressants response in the GENDEP study: Differentiating between baseline 'predictors' and longitudinal 'targets'

Neuropsychopharmacology

Volumn 38, Issue 3, 2013, Pages 377-385

  Cattaneo, Annamaria ^a   Gennarelli, Massimo ^a,b   Uher, Rudolf ^c   Breen, Gerome ^c   Farmer, Anne ^c   Aitchison, Katherine J ^c,d   Craig, Ian W ^c   Anacker, Christoph ^e   Zunsztain, Patricia A ^e   McGuffin, Peter ^c   Pariante, Carmine M ^e  

^a UNIVERSITY OF BRESCIA   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d UNIVERSITY OF ALBERTA   (Canada)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antidepressant; depression; glucocorticoid receptor; inflammation; neuroplasticity; personalised medicine; treatment response

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; ESCITALOPRAM; GLUCOCORTICOID RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MESSENGER RNA; NORTRIPTYLINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HAMILTON SCALE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NERVE CELL PLASTICITY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 84872500205     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.211     Document Type: Erratum

References (65)

1. Anacker C, Zunszain PA, Carvalho LA, Pariante CM (2011). The glucocorticoid receptor: pivot of depression and of antidepres-sant treatment? Psychoneuroendocrinology 36: 415-425.
2. Anacker C, Zunszain PA, Cattaneo A, Carvalho LA, Garabedian MJ, Thuret S et al (2011). Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol Psychiatry 16: 738-750.
3. Bauer ME, Papadopoulos A, Poon L, Perks P, Lightman SL, Checkley S et al (2003). Altered glucocorticoid immunoregula-tion in treatment resistant depression. Psychoneuroendocrinol-ogy 28: 49-65.
4. Bebbington P, Nayani T (1995). The psychosis screening questionnaire. Int J Methods Psychiatr Res 5: 11-19.
5. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961). An inventory for measuring depression. Arch Gen Psychiatry 4: 561-571.
6. Benedetti F, Lucca A, Brambilla F, Colombo C, Smeraldi E (2002). Interleukine-6 serum levels correlate with response to anti-depressant sleep deprivation and sleep phase advance. Prog Neuropsychopharmacol Biol Psychiatry 26: 1167-1170.
7. Binder EB (2009). The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 1: S186-S195.
8. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, Molteni R, Nielsen MG, Placentino A et al (2010). Serum and plasma BDNF levels in major depression: a replication study and meta-analyses. World J Biol Psychiatry 11: 763-773.
9. Calfa G, Kademian S, Ceschin D, Vega G, Rabinovich GA, Volosin M (2003). Characterization and functional significance of glucocorticoid receptors in patients with major depression: modulation by antidepressant treatment. Psychoneuroendocri-nology 28: 687-701.
10. Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D et al (2003). Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and parox-etine treatment. Biol Psychiatry 54: 906-914.
11. Cattaneo A, Bocchio-Chiavetto L, Zanardini R, Milanesi E, Placentino A, Gennarelli M (2010a). Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment Int J Neuropsychopharmacol 13: 103-108.
12. Cattaneo A, Sesta A, Calabrese F, Nielsen G, Riva MA, Gennarelli M (2010b). The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology 35: 1423-1428.
13. Chopra K, Kumar B, Kuhad A (2011). Pathobiological targets of depression. Expert Opin Ther Targets 15: 379-400.
14. Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A (2008). Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 65: 409-415.
15. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK et al (2010). A meta-analysis of cytokines in major depression. Biol Psychiatry 67: 446-457.
16. Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E et al (2011). Cost of disorders of the brain in Europe. Eur Neuropsychopharmacol 21: 718-779.
17. Hamilton M (1967). Development of a rating scale for primary depressive illness. Brit J Clin Psychol 6: 278-296.
18. Hannestad J, DellaGioia N, Bloch M (2011). The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacol 36: 2452-2459.
19. Haroon E, Raison CL, Miller AH (2012). Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behaviour. Neuropsychopharma-cology 37: 137-162.
20. Hiles SA, Baker AL, de Malmanche T, Attia J (2012). Interleukin-6, C-reactive protein and interleukin-10 after antidepressant treatment in people with depression: a meta-analysis. Psychol Med 16: 1-12.
21. Horstmann S, Lucae S, Menke A, Hennings JM, Ising M, Roeske D et al (2010). Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35: 727-740.
22. Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N et al (2007). Combined dexamethasone/corticotropin releasing hor-mone test predicts treatment response in major depression-a potential biomarker? Biol Psychiatry 62: 47-54.
23. Janssen DG, Caniato RN, Verster JC, Baune BT (2010). A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 25: 201-215.
24. Juruena MF, Cleare AJ, Papadopoulos AS, Poon L, Lightman S, Pariante CM (2010). The prednisolone suppression test in depression: dose-response and changes with antidepressant treatment. Psychoneuroendocrinology 35: 1486-1491.
25. Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ (2009). Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry 194: 342-349.
26. Keers R, Uher R, Gupta B, Rietschel M, Schulze TG, Hauser J et al (2010). Stressful life events, cognitive symptoms of depression and response to antidepressants in GENDEP. J Affect Disord 127: 337-342.
27. Kitaichi N, Kotake S, Mizue Y, Sasamoto Y, Goda C, Iwabuchi K et al (2000). High-dose corticosteroid administration induces increase of serum macrophage migration inhibitory factor in patients with Vogt-Koyanagi-Harada's disease. Microbiol Im-munol 44: 1075-1077.
28. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H (2000). Cytokine production and treatment response in major depres-sive disorder. Neuropsychopharmacol 22: 370-379.
29. Lee BH, Kim YK (2010). The roles of BDNF in the pathophysiology of major depression and in antidepressant treatment. Psychiatry Investig 7: 231-235.
30. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJ et al (2008). The FKBP5-gene in depression and treatment response\- an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR&z.ast;D) Cohort. Biol Psychiatry 63: 1103-1110.
31. Melas PA, Rogdaki M, Lennartsson A, Björk K, Qi H, Witasp A et al (2011). Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression. Int J Neuropsychopharmacol 20: 1-11.
32. Menke A, Arloth J, Pütz B, Weber P, Klengel T, Mehta D et al (2012). Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 37: 1455-1464.
33. Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J et al (2011). Serum levels of brain-derived neuro-trophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 16: 1088-1095.
34. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389.
35. Nanni V, Uher R, Danese A (2012). Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry 169: 141-151.
36. Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF et al (2003). Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 100: 14293-14296.
37. O'Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestage J et al (2009). Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 29: 4200-4209.
38. Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Zhang H, Pavuluri MN (2010). Brain-derived neurotrophic factor gene and protein expression in pediatric and adult depressed subjects. Prog Neuropsychopharmacol Biol Psychiatry 34: 645-651.
39. Pariante CM, Alhaj HA, Arulnathan VE, Gallagher P, Hanson A, Massey E et al (2012). Central glucocorticoid receptor-mediated effects of the antidepressant, citalopram, in humans: a study using EEG and cognitive testing. Psychoneuroendocrinology 37: 618-628.
40. Pariante CM, Hye A, Williamson R, Makoff A, Lovestone S, Kerwin RW (2003). The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expres-sion in fibroblasts and rat primary neurones. Neuropsychophar-macol 28: 1553-1561.
41. Pariante CM, Lightman SL (2008). The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31: 464-468.
42. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404.
43. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH (1997). Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 52: 571-581.
44. Pariante CM, Thomas SA, Lovestone S, Makoff A, Kerwin RW (2004). Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinol 29: 423-447.
45. Raison CL, Borisov AS, Woolwine BJ, Massung B, Vogt G, Miller AH (2010). Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflamma-tory cytokines and behavior. Mol Psychiatry 15: 535-547.
46. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G et al (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 15: 393-403.
47. Ribeiro SC, Tandon R, Grunhaus L, Greden JF (1993). The DST as a predictor of outcome in depression: a meta-analysis. Am J Psychiatry 150: 1618-1629.
48. Rojas PS, Fritsch R, Rojas RA, Jara P, Fiedler JL (2011). Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study. Psychiatry Res 189: 239-245.
49. Sluzewska A, Sobieska M, Rybakowski JK (1997). Changes in acute-phase proteins during lithium potentiation of antidepres-sants in refractory depression. Neuropsychobiology 35: 123-127.
50. Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA (2011). Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. Nature 476: 458-461.
51. Spijker AT, van Rossum EF (2012). Glucocorticoid sensitivity in mood disorders. Neuroendocrinology 95: 179-186.
52. Taler M, Gil-Ad I, Lomnitski L, Korov I, Baharav E, Bar M et al (2007). Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol 17: 774-780.
53. Thakker-Varia S, Jean YY, Parikh P, Sizer CF, Jernstedt Ayer J, Parikh A et al (2010). The neuropeptide VGF is reduced in human bipolar postmortem brain and contributes to some of the behavioral and molecular effects of lithium. J Neurosci 30: 9368-9380.
54. Thase ME (2006). Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr 11: 12-21.
55. Uher R (2011). Genes, environments and individual differences in response to treatment. Harv Rev Psychiatry 19: 109-124.
56. Uher R, Farmer A, Maier W, Rietschel M, Hauser J, Marusic A et al (2008). Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 38: 289-300.
57. Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O et al (2009). Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 9: 225-233.
58. Uher R, Perroud N, Ng MY, Hauser J, Henigsberg N, Maier W et al (2010). Genome-wide pharmacogenetics of antidepressant re-sponse in the GENDEP project. Am J Psychiatry 167: 555-564.
59. Uher R, Tansey KE, Malki K, Perlis RH (2012). Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 13: 233-240.
60. Wong ML, Dong C, Maestre-Mesa J, Licinio J (2008). Polymorph-isms in inflammation-related genes are associated with suscept-ibility to major depression and antidepressant response. Mol Psychiatry 13: 800-812.
61. Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J (2009). Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry 33: 722-726.
62. Yu YW, Chen TJ, Hong CJ, Chen HM, Tsai SJ (2003). Association study of the interleukin-1 beta (C-511T) genetic polymorphism with major depressive disorder, associated symptomatology, and antidepressant response. Neuropsychopharmacol 28: 1182-1185.
63. Zhang L, Li H, Su TP, Barker JL, Maric D, Fullerton CS et al (2008). Traumatic Stress Brain Study Group, Ursano R.p11 is up-regulated in the forebrain of stressed rats by glucocorticoid acting via two specific glucocorticoid response elements in the p11 promoter. Neuroscience 153: 1126-1134.
64. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM (2011). Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 722-729.
65. Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM et al (2012). Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogen-esis. Neuropsychopharmacology 37: 939-949.